Extracellular acidosis differentiates pancreatitis and pancreatic cancer in mouse models using acidoCEST MRI
AuthorHigh, Rachel A
Randtke, Edward A
Jones, Kyle M
Lindeman, Leila R
Ma, Jacqueline C
LeRoux, Lucia G
Pagel, Mark D
AffiliationUniv Arizona, Canc Biol Interdisciplinary Program
Univ Arizona, Dept Med Imaging
Univ Arizona, Dept Biomed Engn
MetadataShow full item record
PublisherELSEVIER SCIENCE INC
CitationHigh, R. A., Randtke, E. A., Jones, K. M., Lindeman, L. R., Ma, J. C., Zhang, S., ... & Pagel, M. D. (2019). Extracellular acidosis differentiates pancreatitis and pancreatic cancer in mouse models using acidoCEST MRI. Neoplasia, 21(11), 1085-1090.
RightsCopyright © 2019 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). https://doi.org/10.1016/j.neo.2019.09.004
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractDifferentiating pancreatitis from pancreatic cancer would improve diagnostic specificity, and prognosticating pancreatitis that progresses to pancreatic cancer would also improve diagnoses of pancreas pathology. The high glycolytic metabolism of pancreatic cancer can cause tumor acidosis, and different levels of pancreatitis may also have different levels of acidosis, so that extracellular acidosis may be a diagnostic biomarker for these pathologies. AcidoCEST MRI can noninvasively measure extracellular pH (pHe) in the pancreas and pancreatic tissue. We used acidoCEST MRI to measure pHe in a KC model treated with caerulein, which causes pancreatitis followed by development of pancreatic cancer. We also evaluated the KC model treated with PBS, and wild-type mice treated with caerulein or PBS as controls. The caerulein-treated KC cohort had lower pHe of 6.85–6.92 before and during the first 48 h after initiating treatment, relative to a pHe of 6.92 to 7.05 pHe units for the other cohorts. The pHe of the caerulein-treated KC cohort decreased to 6.79 units at 5 weeks when pancreatic tumors were detected with anatomical MRI, and sustained a pHe of 6.75 units at the 8-week time point. Histopathology was used to evaluate and validate the presence of tumors and inflammation in each cohort. These results showed that acidoCEST MRI can differentiate pancreatic cancer from pancreatitis in this mouse model, but does not appear to differentiate pancreatitis that progresses to pancreatic cancer vs. pancreatitis that does not progress to cancer.
NoteOpen access journal
VersionFinal published version
SponsorsUnited States Department of Health & Human Services National Institutes of Health (NIH) - USA [P30CA23074, P30CA016672]
- Evaluations of extracellular pH within in vivo tumors using acidoCEST MRI.
- Authors: Chen LQ, Howison CM, Jeffery JJ, Robey IF, Kuo PH, Pagel MD
- Issue date: 2014 Nov
- Preliminary Results that Assess Metformin Treatment in a Preclinical Model of Pancreatic Cancer Using Simultaneous [<sup>18</sup>F]FDG PET and acidoCEST MRI.
- Authors: Goldenberg JM, Cárdenas-Rodríguez J, Pagel MD
- Issue date: 2018 Aug
- Clinical Translation of Tumor Acidosis Measurements with AcidoCEST MRI.
- Authors: Jones KM, Randtke EA, Yoshimaru ES, Howison CM, Chalasani P, Klein RR, Chambers SK, Kuo PH, Pagel MD
- Issue date: 2017 Aug
- Evaluations of Tumor Acidosis Within In Vivo Tumor Models Using Parametric Maps Generated with Acido CEST MRI.
- Authors: Chen LQ, Randtke EA, Jones KM, Moon BF, Howison CM, Pagel MD
- Issue date: 2015 Aug
- A comparison of iopromide and iopamidol, two acidoCEST MRI contrast media that measure tumor extracellular pH.
- Authors: Moon BF, Jones KM, Chen LQ, Liu P, Randtke EA, Howison CM, Pagel MD
- Issue date: 2015 Nov-Dec